Redox regulation of transcriptional activators

Free Radical Biology and Medicine

Volumn 21, Issue 3, 1996, Pages 335-348

  Sun, Yi ^a   Oberley, Larry W ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

AP 1; Free radicals; NF B; p53; Redox regulation; Transcription factors activators

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; OXIDIZING AGENT; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1;

HUMAN; NONHUMAN; ONCOGENE C MYB; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVIEW; TRANSACTIVATION;

EID: 0029760957     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/0891-5849(96)00109-8     Document Type: Review

References (133)

1. 1. Wingender, E. Transcription regulating proteins and their recognition sequences. Eukaryotic Gene Exp. 1:11-48; 1990.
2. 2. Buratowski, S. The basics of basal transcription by RNA polymerase II. Cell 77:1-3; 1994.
3. 3. Zawel, L.; Reinberg, D. Initiation of transcription by RNA polymerase II: A multi-step process. Prog. Nucleic Acid Res. Mol. Biol. 44:67-108; 1993.
4. 4. Baeuerle, P. A. The inducible transcription activator NF-κB: Regulation by distinct protein subunits. Biochim. Biophys. Acta 1072:63-80; 1991.
5. 5. Jackson, S. P. Regulating transcription factor activity by phosphorylation. Trends Cell Biol. 2:104-108; 1992.
6. 6. Vogt, P. K.; Bos, T. J. Jun: Oncogene and transcription factor. Adv. Cancer Res. 55:1-35; 1990.
7. 7. Angel, P.; Karin, M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072:129-157; 1991.
8. 8. Maltzman, W.; Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1689-1694; 1984.
9. 9. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6340-6311; 1991.
10. 10. Binetruy, B.; Smeal, T.; Karin, M. Ha-Ras augments c-Jun activity and stimulates phophorylation of its activation domain. Nature 351:122-127; 1991.
11. 11. Smeal, T.; Binetruy, B.; Mercola, D. A.; Birrer, M.; Karin, M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serine 63 and 73. Nature 354:494-496; 1991.
12. 12. Lees, J. A.; Buchkovich, K. J.; Marshak, D. R.; Anderson, C. W.; Harlow, E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 10:4279-4290; 1991.
13. 13. Maxwell, S. A.; Roth, J. A. Postranslational regulation of p53 tumor suppressor protein function. Crit. Rev. Oncog. 5:23-57; 1994.
14. 14. Storz, G.; Tartaglia, L. A.; Ames, B. N. Transcriptional regulator of oxidative stress-inducible genes; Direct activation by oxidation. Science 248:189-194; 1990.
15. 15. Allen, F. Redox control of transcription: Sensors, response regulators, activators and repressors. FEBS Lett. 332:203-207; 1993.
16. 16. Hidalgo, E.; Demple, B. An iron-sulfur center essential for transcriptional activation by the redox-sensing SoxR protein. EMBO J. 13:138-146; 1994.
17. 17. Demple, B.; Amábile-Cuevas, C. F. Redox redux: The control of oxidative stress responses. Cell 67:837-839; 1991.
18. 18. Ostrovsky de Spicer, P.; Maloy, S. PutA protein, a membrane-associated flavin dehydrogenase, acts as a redox-dependent transcriptional regulator. Proc. Natl. Acad. Sci. USA 90:4295-4298; 1993.
19. 19. Halliwell, B.; Gutteridge, J. M. C. eds. Free Radicals in Biology and Medicine. 2nd ed. Oxford: Clarendon Press; 1989; 1989.
20. 20. Lane, D. P. P53 and human cancers. Br. Med. Bull. 50:582-599; 1994.
21. 21. El-Deiry, W. S.; Kern, S.; Pietenpol, J. A.; Kinzler, K. W.; Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49; 1992.
22. 22. Baker, S. J.; Markowitz, S.; Fearon, E. R.; Willson, J. K.; Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wildtype p53. Science 249:912-915; 1990.
23. 23. Land, D. P. P53, guardian of the genome. Nature 358:15-16; 1992.
24. 24. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546; 1992.
25. 25. Greenblatt, M. S.; Bennett, W. P.; Hollstein, M.; Harris, C. C. Mutations in the p53 suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878; 1994.
26. 26. Zakut-Houri, R.; Bienz-Tadmor, B.; Givol, D.; Oren, M. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 4:1251-1255; 1985.
27. 27. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. P53 mutations in human cancers. Science 253:49-53; 1991.
28. 28. De Vries, E. M.; Ricke, D. O.; De Vries, T. N.; Hartmann, A.; Blaszyk, H.; Liao, D.; Soussi, T.; Kovach, J. S.; Sommer, S. Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. Hum. Mutat. 7:202-213; 1996.
29. 29. Cho, Y.; Gorina, S.; Jeffrey, P. D.; Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355; 1994.
30. 30. Hainaut, P.; Milner, J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:4469-4473: 1993.
31. 31. Hainaut, P.; Rolley, N.; Davies, M.; Milner, J. Modulation by copper of p53 conformation and sequence-specific DNA binding: Role for Cu(II)/Cu(I) redox mechanism. Oncogene 10:27-32; 1995.
32. 32. Hainaut, P.; Milner, J. A structural role of metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res. 53:1739-1742: 1993.
33. 33. Butcher, S.; Hainaut, P.; Milner, J. Increased salt concentration reversibly destabilizes p53 quaternary structure and sequence-specific DNA binding. Biochem. J. 298:513-516; 1994.
34. 34. Hainaut, P.; Butcher, S.; Milner, J. Temperature sensitivity for conformation is an intrinsic property of wild type p53. Br. J. Cancer 71:227-231; 1995.
35. 35. Hupp, T. R.; Meek, D. W.; Midgley, C. A.; Lane, D. P. Activation of the cryptic DNA binding function of mutant form of p53. Nucleic Acids Res. 21:3167-3174; 1993.
36. 36. Srinivasan, R.; Roth, J. A.; Maxwell, S. A. Sequence-specific interaction of a conformational domain of p53 with DNA. Cancer Res. 53:5361-5364; 1993.
37. 37. Pavletich, N. P.; Chambers, K. A.; Pabo, C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spot. Genes Dev. 7:2556-2564; 1993.
38. 38. Rainwater, R.; Parks, D.; Anderson, M. E.; Tegtmeyer, P.; Mann, K. Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol. 15:3892-3903; 1995.
39. 39. Sun, Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Radic. Biol. Med. 8:583-599; 1990.
40. 40. Juven, T.; Barak, Y.; Zauberman, A.; George, D. L.; Oren, M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416; 1993.
41. 41. El-Deiry, W. S.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF-1, a potential mediator of p53 tumor suppression. Cell 75:817-825; 1993.
42. 42. Kern, S. E.; Kinzler, K. W.; Bruskin, A.; Jarosz, D.; Friedman, P.; Prives, C.; Vogelstein, B. Identification of p53 as a sequence-specific DNA binding protein. Science 252:1708-1711; 1991.
43. 43. Sun, Y.; Nakamura, K.; Hegamyer, G. A.; Dong, Z.; Colburn, N. H. No point mutation of Ha-ras or p53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Mol. Carcinog. 8:49-57; 1993.
44. 44. Sun, Y.; Hegamyer, G.; Nakamura, K.; Kim, H.; Oberley, L. W.; Colburn, N. H. Alterations of the p53 tumor suppressor gene in transformed mouse liver cells. Int. J. Cancer 55:952-956; 1993.
45. 45. Sun, Y.; Nakamura, K.; Wendel, E.; Colburn, N. H. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 90:2827-2831; 1993.
46. 46. Sun, Y.; Dong, Z.; Nakamura, K.; Colburn, N. H. Dosage dependent dominace over wild type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J. 7:944-950; 1993.
47. 47. Meyer, M.; Pahl, H. L.; Baeuerle, P. A. Regulation of the transcription factors NF-κB and AP-1 by redox changes. Chem. Biol. Interact. 91:91-100; 1994.
48. 48. Abate, C.; Luk, D.; Gentz, R.; Rauscher, F. J., , III; Curran, T. Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc. Natl. Acad. Sci. USA 87:1032-1036; 1990.
49. 49. Abate, C.; Patel, L.; Rauscher, F. J., III; Curran, T. Redox regulation of Fos and Jun DNA-binding activity in vitro. Science 249:1157-1161; 1990.
50. 50. Toledano, M. B.; Leonard, W. J. Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA 88:4328-4332; 1991.
51. 51. Galter, D.; Mihm, S.; Droge, W. Distinct effects of glutathione disulphide on the nuclear transcripton factor κB and the activator protein-1. Eur. J. Biochem. 221:639-648; 1994.
52. 52. Bannister, A. J.; Cook, A.; Kouzarides, T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Onogene 6:1243-1250; 1991.
53. 53. Handel, M. L.; Watts, C. K. W.; DeFazio, A.; Day, R. O.; Sutherland, R. L. Inhibition of AP-1 binding and transcription by gold and selenium involving conseved cysteine residues in Jun and Fos. Proc. Natl. Acad. Sci. USA 92:4497-4501; 1995.
54. 54. Xanthoudakis, S.; Curran, T. Identification and characterization of Ref-1, nuclear protein that facilitates AP-1 DNA-binding activily. EMBO J. 11:653-665; 1992.
55. 55. Xanthoudakis, S.; Miao, G.; Wang, F.; Pan, Y. E.; Curran, T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J. 11:3323-3335; 1992.
56. 56. Robson, C. N.; Hickson, I. D. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. Coli xth (exonuclease III) mutants. Nucleic Acids Res. 19:5519-5523; 1991.
57. 57. Demple, B.; Herman, T.; Chen, D. S. Cloning and expression of APE. the cDNA encoding the major human apurinic endonuclease: Definition of a family of DNA repair enzymes. Proc. Natl. Acad. Sci. USA 88:11450-11454; 1991.
58. 58. Xanthoudakis, S.; Miao, G. G.; Curran, T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. USA 91:23-27; 1994.
59. 59. Walker, L. J.; Robson, C. N.; Black, E.; Gillespie, D.; Hickson, I. D. Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol. Cell. Biol. 13:5370-5376; 1993.
60. 2 and N-acetyl-L-cysteine regulate expression of c-jun and c-fos in lens systems. Exp. Eye Res. 59:179-190; 1994.
61. 61. Holmgren, A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264:13963-13966; 1989.
62. 62. Schenk, H.; Klein, M.; Erdbrugger, W.; Dröge, W; Schulze-Osthoff, K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc. Natl. Acad. Sci. USA 91:1672-1676; 1994.
63. 63. Bergelson, S.; Pinkus, R.; Daniel, V. Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression. Cancer Res. 54:36-40; 1994.
64. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12:2005-2015; 1993.
65. 65. Maki, Y.; Bos, T. J.; Davis, M.; Starbuck, M.; Vogt, P. K. Avian sarcoma virus 17 carries the Jun oncogene. Proc. Natl. Acad. Sci. USA 84:2828-2832; 1987.
66. 66. Okuno, H.; Akahori, A.; Sato, H.; Xanthoudakis, S.; Curran, T.; Iba, H. Escape from redox regulation enhances the transforming activity of Fos. Oncogene 8:695-701; 1993.
67. 2 is directly related to increased proliferation and transformation of tracheal epithelial cells. Cancer Res. 55:2723-2726; 1995.
68. 68. Colburn, N. H. Gene regulation by active oxygen and other stress inducers: Role in tumor promotion and progression. In: Spatz, L.; Bloom, A. D. eds. Biological consequences of oxidative stress: Implications for cardiovascular disease and carcinogenesis. London: Oxford University Press; 1992; 1992:121-137.
69. 69. Watts, R. G.; Ben-Ari, E. T.; Bernstein, L. R.; Birrer, M. J.; Winterstein, D.; Wendel, E.; Colburn, N. H. C-jun and multi-stage carcinogenesis: Association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation. Mol. Carcinog. 13:27-36; 1995.
70. 70. Yoshioka, K.; Deng, T.; Cavigelli, M.; Karin, M. Antitumor promotion by phenolic antioxidants: Inhibition of AP-1 activity through induction of Fra expression. Proc. Natl. Acad. Sci. USA 92:4972-4976; 1995.
71. 71. Bours, V.; Villalobos, J.; Burd, P. R.; Kelly, K.; Siebenlist, U. Cloning of a mitogen-inducible gene encoding a κB DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature 348:76-80; 1990.
72. 72. Kieran, M.; Blank, V.; Logeat, F.; Vandekerckhove, J.; Lottspeich, F.; Le Bail, O.; Urban, M. B.; Kourilsky, P.; Baeuerle, P. A.; Israel, A. The DNA binding subunit of NF-κB is identical to factor KBF1 and homologous to the rel oncogene product. Cell 62:1007-1018; 1990.
73. 73. Ghosh, S.; Gifford, A. M.; Riviere, L. R.; Tempst, P.; Nolan, G. P.; Baltimore, D. Cloning of the p50 DNA binding subunit of NF-κB: Homology to rel and dorsal.. Cell 62:1019-1029; 1990.
74. 74. Bull, P.; Morley, K. L.; Hoekstra, M. F.; Hunter, T.; Verma, I. M. The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol. Cell. Biol. 10:5473-5485; 1990.
75. 75. Baeuerle, P. A.; Baltimore, D. IκB: A specific inhibitor of the NF-κB transcription factor. Science 242:540-546; 1988.
76. 76. Naumann, M.; Scheidereit, C. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J. 13:4597-4607; 1994.
77. 77. Hayashi, T.; Sekine, T.; Okamoto, T. Identification of a new serine kinase that activates NF-κB by direct phosphorylation. J. Biol. Chem. 268:26790-26795; 1993.
78. 78. Henkel, T.; Machleidt, T.; Alkalay, I.; Kronke, M.; Ben-Neriah, Y.; Baeuerle, P. A. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 365:182-185; 1993.
79. 79. Baeuerle, P. A.; Henkel, T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12:141-179; 1994.
80. 80. Higgins, K. A.; Perez, J. R.; Coleman, T. A.; Dorshkind, K.; McComas, W. A.; Sarmiento, U. M.; Rosen, C. A.; Narayanan, R. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90:9901-9905; 1993.
81. 81. Kaltschmidt, B.; Baeuerle, P. A.; Kaltschmidt, C. Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol. Aspects Med. 14:171-190; 1993.
82. 82. Matthews, J. R.; Wakasugi, N.; Virelizier, J. L; Yodoi, J.; Hay, R. T. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 20:3821-3830; 1992.
83. 83. Mitomo, K.; Nakayama, K.; Fujimoto, K.; Sun, X.; Seki, S.; Yamamoto, K. Two different cellular redox systems regulate the DNA-binding activity of the p50 subunit of NF-κB in vitro. Gene 145:197-203; 1994.
84. 84. Hayashi, T.; Ueno, Y.; Okamoto, T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268:11380-11388; 1993.
85. 85. Kumar, S.; Rabson, A. B.; Gelinas, C. The RxxRxRxxC motif conserved in all Rel/κB proteins is essential for the DNA binding activity and redox regulation of the v-Rel oncoprotein. Mol. Cell. Biol. 12:3094-3106; 1992.
86. 86. Okamoto, T.; Ogiwara, H.; Hayashi, T.; Mitsui, A.; Kawabe, T.; Yodoi, J. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol. 4:811-819; 1992.
87. 87. Schreck, R.; Meier, B.; Mannel, D. N.; Droge, W.; Baeuerle, P. A. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J. Exp. Med. 175:1181-1194; 1992.
88. 88. Israel, N.; Gougerol-Pocidalo, M. A.; Aillet, F.; Virelizier, J. L. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal activity in human T and monocytic cell lines. J. Immunol. 149:3386-3393; 1992.
89. 89. Schreck, F.; Rieber, P.; Baeuerle, P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:2247-2258; 1991.
90. 90. Staal, F. J. T.; Roederer, M.; Herzenberg, L. A.; Herzenberg, L. A. Intracellular thiols regulate activation of nuclear factor κB and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 87:9943-9947; 1990.
91. LCK in T cells. Oncogene 8:3133-3139; 1993.
92. 92. Anderson, M. T.; Staal, F. J. T.; Gitler, C.; Hersenberg, L. A.; Hersenberg. L. A. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc. Natl. Acad. Sci. USA 91:11527-11531; 1994.
93. 93. Menon, S. D.; Qin, S.; Guy, G. R.; Tan, T. H. Differential induction of nuclear NF-κB by protein phosphatase inhibitors in primary and transformed human cells: Requirement for both oxidation and phosphorylation in nuclear translocation. J. Biol. Chem. 268:26805-26812; 1993.
94. 94. Staal, F. J. T.; Anderson, M. T.; Staal, G. E. J.; Hersenberg, L. A.; Gitler, C.; Hersenberg, L. A. Redox regulation of signal transduction: Tyrosine phosphorylation and calcium influx. Proc. Natl. Acad. Sci. USA 91:3619-3622; 1994.
95. 95. Talley, A. K.; Dewhurst, S.; Perry, S.; Dollard, S. C.; Gummuluru, S.; Fine, S. M.; New, D.; Epstein, L. G.; Gendelman, H. E.; Gelbard, H. A. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: Protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol. Cell. Biol. 15:2359-2366; 1995.
96. 96. Shen-Ong, G. L. C. The myb oncogene. Biochim. Biophys. Acta 1032:39-52; 1990.
97. 97. Guehmann, S.; Vorbrueggen, G.; Kalkbrenner, F.; Moelling, K. Reduction of a conserved Cys is essential for Myb DNA-binding. Nucleic Acids Res. 20:2279-2286; 1992.
98. 98. Myrset, A. H.; Bostad, A.; Jamin, N.; Lirsac, P. N.; Toma, F.; Gabrielsen, O. S. DNA and redox state induced conformational changes in the DNA-binding domain of the Myb oncoprotein. EMBO J. 12:4625-1633; 1993.
99. 99. Grasser, F. A.; LaMontagne, K.; Whittaker, L.; Stohr, S.; Lipsick. J. S. A highly conserved cysteine in the v-Myb DNA binding domain is essential for transformation and transcriptional trans-activation. Oncogene 7:1005-1009; 1992.
100. 100. Wasylyk, B.; Hahn, S. L.; Giovane, A. The Ets family of transcription factors. Eur. J. Biochem. 211:7-18; 1993.
101. 101. Wasylyk, B.; Wasylyk, C.; Flores, P.; Begue, A.; Leprince, D.; Stehelin, D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature 346:191-193; 1990.
102. 102. Wasylyk, C.; Wasylyk, B. Oncogenic conversion of Ets affects redox regulation in vivo and in vitro. Nucleic Acids Res. 21:523-529; 1993.
103. 103. Suzuki, H.; Romano-Spica, V.; Papas, T.; Bhat, N. ETS1 suppresses tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. USA 92:4442-4446; 1995.
104. 104. Kadonaga, J. T.; Garner, K. R.; Masiarz, F. R.; Tjian, R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51:1079-1090; 1987.
105. 105. Westin, G.; Schaffner, W. Heavy metal ions in transcription factors from HeLa cells:Sp1, but not octamer transcription factor requires zinc for DNA binding and for activator function. Nucleic Acids Res. 16:5771-5781; 1988.
106. 106. Knoepfel, L.; Steinkühler, C.; Carrì, M.-T.; Rotilio, G. Role of zinc-coordination and of the glutathione redox couple in the redox susceptibility of human transcription factor SP1. Biochem. Biophys. Res. Commun. 201:871-877; 1994.
107. 107. Ammendola, R.; Mesuraca, M.; Russo, T.; Cimino, F. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J. Biol. Chem. 267:17944-17948; 1992.
108. 108. Ammendola, R.; Mesuraca, M.; Russo, T.; Cimino, F. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur. J. Biochem. 225:483-489; 1994.
109. 109. Payvar, F.; DeFranco, D.; Firestone, G. L.; Edgar, B.; Wrange, O.; Okret, S.; Gustafsson, J.-A.; Yamamoto, K. R. Sequence-specific binding of glucocorticoid receptor to MTV DNA at sites within and upstream of the transcribed region. Cell 35:381-392; 1983.
110. 110. Freedman, L. F.; Luisi, B. F.; Korszun, Z. R.; Basavappa, R.; Sigler, P. B.; Yamamoto, K. R. The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature 334:543-546; 1988.
111. 111. Schaumburg, B. P. Investigations on the glucocorticoid-binding protein from rat thymocytes: II. Stability, kinetics and specificity of binding of steroids. Biochim. Biophys. Acta 261:219-235: 1972.
112. 112. Grippo, J. F.; Holmgren, A.; Pratt, W. B. Proof that the endogenous, heat-stable glucocorticoid receptor-activating factor is thioredoxin. J. Biol. Chem. 260:93-97; 1985.
113. 113. Bodwell, J. E.; Holbrook, N. J.; Munck, A. Evidence for distinct sulfhydryl groups associated with steroid-and DNA-binding domains of rat thymus glucocorticoid receptors. Biochemistry 23:4237-4242; 1984.
114. 114. Tienrungroj, W.; Meshinchi, S.; Sanchez, E. R.; Pratt, S. E.; Grippo, J. F.; Holmgren, A.; Pratt, W. B. The role of sulfhydryl groups in permitting transformation and DNA binding of the glucocorticoid receptor. J. Biol. Chem. 262:6992-7000; 1987.
115. 115. Esposio, F.; Cuccovillo, F.; Morra, F.; Russo, T.; Cimino, F. DNA binding activity of the glucocorticoid receptor is sensitive to redox changes in intact cells. Biochim. Biophys. Acta 1260:308-314; 1995.
116. 116. Roth, G. S.; Livingston, J. N. Dissociation of glucocorticoid inhibition of glucose transport and metabolism by increase in adipocyte age and/or size. Endocrinology 104:423-428; 1979.
117. 117. Sukhatme, V. P.; Cao, X.-M.; Change, E. C.; Tsaimorris, C.-H.; Stamenkovich, D.; Ferreira. P. C. P.; Cohen, D. R.; Edwards, S. A.; Shows, T. B.; Curran, T.; LeBeau, M. M.; Adamson, E. D. A zinc-ringer encoding gene co-regulated with c-fos during growth and differentiation and after cellular depolarization. Cell 53:37-43; 1988.
118. 118. Huang, R.-P.; Adamson, E. D. Characterization of the DNA-binding properties of the early growth response-1 (Egr-1) transcription factor; Evidence for modulation by a redox mechanism. DNA Cell Biol. 12:265-273; 1993.
119. 119. Esposito, F.; Agosti, V.; Morrone, G.; Morra, F.; Cuomo, C.; Russo, T.; Venuta, S.; Cimino, F. Inhibition of the differentiation of human myeloid cell lines by redox changes induced through glutathione depletion. Biochem. J. 301:649-653; 1994.
120. 120. Arnone, M. I.; Zannini, M.; Di Lauro, R. The DNA binding activity and the dimerization ability of the thyroid transcription factor I are redox regulated. J. Biol. Chem. 270:12048-12055; 1995.
121. 121. Civitareale, D.; Saiardi, A.; Falasca, P. Purification and characterization of thyroid transcription factor 2. Biochem. J. 304:981-985; 1994.
122. 122. Pognonec, P.; Roeder, R. G. Recombinant 43-kDa USF binds to DNA and activates transcription in a manner indistinguishable from that of natural 43/44-kDa USF. Mol. Cell. Biol. 11:5125-5136; 1991.
123. 123. Pognonec, P.; Kato, H.; Roeder, R. G. The Helix-Loop-Helix/ Leucine repeat transcription fractor USF can be functionally regulated in a redox-dependent manner. J. Biol. Chem. 267:24563-24567; 1992.
124. 124. Nebert, D. W.; Puga, A.; Vasiliou, S. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann. NY Acad. Sci. 685:624-640; 1993.
125. 125. Reyes, H.; Reisz-Porszasz, S.; Hankinson, O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256:1193-1195; 1992.
126. 126. Lusska, A.; Shen, E.; Whitlock, J. P., Jr. Analysis of protein-DNA interactions at a dioxin-responsive enhancer. J. Biol. Chem. 268:680-685; 1993.
127. 127. Nebert, D. W. The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 20:153-174; 1989.
128. 128. Ireland, R. C.; Li, S.-Y.; Dougherty, J. J. The DNA binding of purified Ah receptor heterodimer is regulated by redox conditions. Arch. Biochem. Biophys. 319:470-480; 1995.
129. 129. Call, K. M.; Glaser, T.; Ito, C. Y.; Buckler, A. J.; Pelletier, J.; Haber, D. A.; Rose, E. A.; Krai, A.; Yeger, H.; Lewis, W. H.; Jones, C.; Housman, D. E. Isolation and characterization of a zinc-finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Ceil 60:509-520; 1990.
130. 130. Ory, K.; Legros, Y.; Auguin, C.; Soussi, T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13:3496-3504; 1994.
131. 131. Stein, B.; Baldwin, A. S., Jr.; Ballard, D. W.; Greene, W. C.; Angel, P.; Herrlich, P. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12:3879-3891; 1993.
132. 132. Goldberg, Y.; Treier, M.; Ghysdael, J.; Bohmann, D. Repression of AP-1 -stimulated transcription by c-Ets-1. J. Biol. Chem. 269:16566-16573; 1994.
133. 133. Masquilier, D.; Sassone-Corsi, P. Transcriptional cross-talk: Nuclear factor CREM and CREB bind to AP-1 sites and inhibit activation by Jun. J. Biol. Chem. 267:22460-22466; 1992.